Opportunities and potential impact for blood-based biomarkers in the advancements of neurodegenerative disease diagnostics

Description

This webinar will discuss technological advancements in the utilization of blood-based biomarkers (BBBM) for early detection and monitoring of neurodegenerative diseases (NDD) such as Alzheimer's disease. Our speaker, Dr. David Wolk, will share the disease application of these biomarkers and explore how they can enhance diagnostic accuracy and patient outcomes. Additionally, he will discuss the integration of blood-based biomarkers at the specialist as well as primary care level. Attendees will gain an understanding of the current landscape, challenges, and future directions in this rapidly evolving field.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Describe the historical context and key differences in pathologies within the NDD space.
• Explore the integration and application of BBBM in clinical settings.
• Recognize the significance of diverse cohorts in BBBM research.
• Identify the challenges and future directions for BBBM in NDD.

Faculty

David A. Wolk, MD
Professor
Director, Alzheimer’s Disease Research Center
Co-Director, Penn Institute on Aging
Co-Director, Penn Memory Center
Division Chief, Cognitive Neurology
Department of Neurology
University of Pennsylvania
Philadelphia, PA

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• David A. Wolk, MD
  • Consulting fees: Beckman Coulter, Eli Lilly, GSK
  • Grand and/or Research Support: Biogen

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID #4406. This activity was planned in accordance with ACCENT® Standards and Policies.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].